Saano V, Hansen P P, Paronen P
Department of Pharmacology and Toxicology, University of Kuopio, Finland.
Pharmacol Toxicol. 1992 Feb;70(2):135-9. doi: 10.1111/j.1600-0773.1992.tb00443.x.
A randomised, placebo-controlled, double blind single-dose cross-over study was arranged to investigate possible interactions between zopiclone (7.5 mg) and two widely used benzodiazepine (BZD) anxiolytics diazepam (5 mg) and lorazepam (1 mg) during the elimination phase of drugs. Psychomotor performance was tested before and 1, 6, 8, 12 and 24 hr after the drug administration. Simultaneously, blood samples were drawn for determination of plasma drug concentrations. The elimination of each compound was not altered by coadministration of other drugs. As expected, one hour after drug ingestion, psychomotor performance was impaired. The coadministration of drugs increased the effect. During the elimination phase, 6 and 8 hr after the drug intake, only zopiclone and lorazepam in combination slightly impaired performance as compared with the pretreatment levels, but there was no difference as compared with placebo. Adverse events after active treatments were not significantly different from those after placebo. At the recommended dose of 7.5 mg, zopiclone does not alter the elimination pharmacokinetics of the BZD anxiolytics diazepam (5mg) and lorazepam (1 mg), and neither is the elimination of zopiclone affected by these BZDs. Due to the rapid elimination of zopiclone, the increase in sedation seen after concurrent administration with BZDs is of short duration.
安排了一项随机、安慰剂对照、双盲单剂量交叉研究,以调查佐匹克隆(7.5毫克)与两种广泛使用的苯二氮䓬(BZD)抗焦虑药地西泮(5毫克)和劳拉西泮(1毫克)在药物消除阶段可能存在的相互作用。在给药前以及给药后1、6、8、12和24小时测试精神运动表现。同时,采集血样以测定血浆药物浓度。每种化合物的消除不受其他药物合用的影响。正如预期的那样,服药一小时后,精神运动表现受到损害。药物合用增强了这种影响。在消除阶段,服药后6和8小时,与预处理水平相比,只有佐匹克隆和劳拉西泮联合使用时轻微损害了表现,但与安慰剂相比没有差异。积极治疗后的不良事件与安慰剂后的不良事件没有显著差异。在推荐剂量7.5毫克下,佐匹克隆不会改变BZD抗焦虑药地西泮(5毫克)和劳拉西泮(1毫克)的消除药代动力学,这些BZD也不会影响佐匹克隆的消除。由于佐匹克隆消除迅速,与BZD同时给药后出现的镇静作用增强持续时间较短。